论文部分内容阅读
目的观察不同浓度的阿托伐他汀对急性冠状动脉(冠脉)综合征早期超敏C反应蛋白(hs-CRP)及B型尿钠肽(BNP)的影响。方法 80例急性冠脉综合征并择期行经皮冠状动脉介入治疗(PCI)的住院患者,按随机序列号法将其分为常规剂量组和强化剂量组,每组40例。两组患者均接受常规药物治疗,常规剂量组:予阿托伐他汀常规剂量维持,术前术后均为20 mg/d;强化剂量组:术前术后阿托伐他汀剂量均为40 mg/d。比较两组不同时间的hs-CRP、BNP水平。结果两组PCI术前hs-CRP、BNP水平比较差异均无统计学意义(P>0.05);强化剂量组PCI术后3、7、14d hs-CRP水平[(4.39±0.50)、(3.31±0.30)、(3.05±0.50)mg/L]、BNP水平[(145.34±4.65)、(112.17±3.85)、(80.38±3.21)pg/ml]均低于常规剂量组hs-CRP水平[(4.64±0.40)、(4.08±0.40)、(3.95±0.50)mg/L]、BNP水平[(151.13±4.23)、(135.15±3.24)、(112.26±3.61)pg/ml],差异均具有统计学意义(P<0.05)。结论阿托伐他汀40 mg/d强化治疗可降低hs-CRP和BNP水平,在急性冠脉综合征的治疗中具有重要作用。
Objective To observe the effects of different concentrations of atorvastatin on early-stage hs-CRP and BNP in patients with acute coronary syndrome (ACS). Methods Eighty patients with acute coronary syndrome who underwent percutaneous coronary intervention (PCI) undergoing elective PCI were enrolled in this study. They were divided into routine dose group and intensive dose group according to random serial number method, 40 patients in each group. The two groups of patients received routine medical treatment, conventional dose group: conventional dose of atorvastatin was maintained, preoperative and postoperative were 20 mg / d; intensive dose group: preoperative and postoperative atorvastatin dose were 40 mg / d. The hs-CRP and BNP levels were compared between two groups at different time points. Results There was no significant difference in hs-CRP and BNP levels between the two groups before PCI (P> 0.05). The levels of hs-CRP at the 3rd, 7th, (3.05 ± 0.50) mg / L], BNP levels [(145.34 ± 4.65), (112.17 ± 3.85) and (80.38 ± 3.21) pg / ml] ± 0.40), (4.08 ± 0.40) and (3.95 ± 0.50) mg / L, respectively. The levels of BNP were (151.13 ± 4.23), (135.15 ± 3.24) and (112.26 ± 3.61) pg / ml, Significance (P <0.05). Conclusion Atorvastatin 40 mg / d intensive treatment can reduce hs-CRP and BNP levels in the treatment of acute coronary syndrome plays an important role.